Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to pick the first fruits from the pact. Gilead is paying $35 million upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback